ArticleNature2023
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
Open access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.
0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 133 citations in OpenAlex.
- UNC5B regulates epithelial-to-mesenchymal transition through a SRC-ZEB1 signaling axis to facilitate pancreatic cancer metastasis.Oncogene · 2026Article
- Inference of secreted protein signaling activities in intercellular communication.Nature methods · 2026Article
- High glucose promotes aggressive progression of PR-negative endometrial cancer via CD146.Journal of translational medicine · 2026Article
- Spatial transcriptomics in cancer research: insights into tumorigenesis, diagnosis and therapeutics.Cell death discovery · 2026Review
- Generation of a stable mouse endometrial tumor-derived cell line using conditional reprogramming.Biological research · 2026Article
- Article
- Hallmarks of epithelial-mesenchymal plasticity in cancer.Molecular cancer · 2026Review
- Cell death pathways and targeting therapeutics in cancer therapy.Acta pharmacologica Sinica · 2026Review
- New biological insights into osteosarcoma-lessons from single cell sequencing studies.Cancer metastasis reviews · 2026Review
- Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.Nature communications · 2026Article
- EMTscore infers divergent EMT pathways from omics data and enables rapid screening for EMT-associated gene sets.Bioinformatics (Oxford, England) · 2026Article
- Deciphering functional intra-tumoral heterogeneity in BRAFOncogene · 2026Article
- UNC5B activates hepatic stellate cells and promotes liver fibrosis via FAK.Cell communication and signaling : CCS · 2026Article
- Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1.Cancer research · 2026Article
- Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells.Journal for immunotherapy of cancer · 2026Article
- Real-Time and High-Resolution NIR-II-L Imaging of Netrin-1-Mediated Neurovascular Coupling Driven by Dose-Dependent Electroacupuncture.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity.Nature cancer · 2026Review
- Frazzled/DCC directs spatial progenitor integration ensuring steady-state intestinal turnover.Nature communications · 2026Article
- Applications of single-cell transcriptomics: updated insights in endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Netrin-1 disrupt high-fat-diet-induced adipogenesis via the PPARγ and Wnt/β-catenin signaling pathways.Communications biology · 2026Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
33 authors at 7 institutions in 3 countries.
Philippe A CassierCentre Léon Bérard, Departement de Recherche Clinique, Centre de recherche en cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Raul Navaridas *Basic Medical Sciences Department Oncological Pathology Group, Institut de Recerca Biomèdica de Lleida, Universidad de Lleida, Lleida, Spain.ORCID 0000-0003-1622-5311
Melanie Bellina *Apoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Nicolas Rama *Apoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.ORCID 0000-0003-1614-7755
Benjamin Ducarouge *Netris Pharma, Lyon, France.ORCID 0000-0002-6701-0508
Hector Hernandez-Vargas *Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR 5286, Centre Léon Bérard, Claude Bernard Lyon 1 University, Lyon, France.ORCID 0000-0001-6045-2103
Jean-Pierre Delord *Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
Justine LengrandApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Andrea ParadisiApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.ORCID 0000-0003-2218-3859
Laurent FattetApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.ORCID 0000-0001-5152-4937
Gwenaële GarinCentre Léon Bérard, Departement de Recherche Clinique, Centre de recherche en cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Hanane GheitCentre Léon Bérard, Departement de Recherche Clinique, Centre de recherche en cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Cecile DalbanCentre Léon Bérard, Departement de Recherche Clinique, Centre de recherche en cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Ievgenia PastushenkoLaboratory of Stem Cells and Cancer, WEL Research Institute, Université Libre de Bruxelles, Brussels, Belgium.
David NevesApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Remy JelinApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Nicolas GadotCRCL Core facilities, Centre de Recherche en Cancérologie de Lyon (CRCL) INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Nicolas BraissandApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Sophie LéonCRCL Core facilities, Centre de Recherche en Cancérologie de Lyon (CRCL) INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Cyril DegletagneCRCL Core facilities, Centre de Recherche en Cancérologie de Lyon (CRCL) INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Xavier Matias-GuiuBasic Medical Sciences Department Oncological Pathology Group, Institut de Recerca Biomèdica de Lleida, Universidad de Lleida, Lleida, Spain.
Mojgan Devouassoux-ShisheboranHospices Civils de Lyon, Department of Pathology, Lyon, France.
Eliane Mery-LamarcheDepartment of Pathology, IUCT-Oncopole, Toulouse, France.
Justine AllardDIAPath, Center for microscopy and molecular Imaging, Université Libre de Bruxelles, Gosselies, Belgium.
Egor ZindyDIAPath, Center for microscopy and molecular Imaging, Université Libre de Bruxelles, Gosselies, Belgium.
Christine DecaesteckerDIAPath, Center for microscopy and molecular Imaging, Université Libre de Bruxelles, Gosselies, Belgium.
Isabelle SalmonDIAPath, Center for microscopy and molecular Imaging, Université Libre de Bruxelles, Gosselies, Belgium.
David PerolCentre Léon Bérard, Departement de Recherche Clinique, Centre de recherche en cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.
Xavi DolcetBasic Medical Sciences Department Oncological Pathology Group, Institut de Recerca Biomèdica de Lleida, Universidad de Lleida, Lleida, Spain.
Isabelle Ray-CoquardCentre Léon Bérard, Departement de Recherche Clinique, Centre de recherche en cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France.ORCID 0000-0003-2472-8306
Cédric BlanpainLaboratory of Stem Cells and Cancer, WEL Research Institute, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-4028-4322
Agnès BernetApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France. agnes.bernet@lyon.unicancer.fr.ORCID 0000-0002-8260-9711
Patrick MehlenApoptosis, Cancer and Development Laboratory - Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Centre de Recherche en Cancérologie de Lyon INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, Lyon, France. patrick.mehlen@lyon.unicancer.fr.ORCID 0000-0003-1743-5417
Université Claude Bernard Lyon 1 · FRUniversité Libre de Bruxelles · BEInstituto de Investigación Biomédica de Lleida · ESHospices Civils de Lyon · FRInstitut Claudius Regaud · FRInstitut universitaire du cancer de Toulouse Oncopole · FRNetris Pharma (France) · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Netrin-1 is upregulated in cancers as a protumoural mechanism
Indexed as
Antibodies, Monoclonal, HumanizedEndometrial NeoplasmsEpithelial-Mesenchymal TransitionNetrin-1AnimalsBiopsyCarboplatinDisease Models, AnimalDrug Resistance, NeoplasmFemaleGene Expression ProfilingHumansMicePaclitaxelRNA-SeqSingle-Cell Gene Expression AnalysisAntibodies, Monoclonal, HumanizedCarboplatinNetrin-1netrin-1 inhibitor NP137NTN1 protein, humanNtn1 protein, mousePaclitaxel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.